glp-1 news 2025 october 21 Consumers' Expectations about Drugs Economic Impact on Food System Players GLP-1 Weight-Loss Drug Demonstration Begins

Weight loss was consistent and progressive, starting at 3.93% at three months and reaching 7.87% at twelve months. In addition, several case series studies have demonstrated benefits of GLP-1s in kidney and pancreas transplant recipients, including lowering blood glucose levels and providing renal protective effects. GLP-1 RAs would be advantageous in liver transplant recipients due to their renal clearance, avoiding interference with immunosuppressant drug metabolism

One prior in vivo study failed to detect elevated levels of GLP-1 in the blood after oral administration of the TRPA1 channels activators cinnamaldehyde and methyl syringate to mice 23

GLP-1 therapy works best as part of a plan, not a quick fix

Bodybuilding Health+ sells one-time bundles instead of a subscription

Novo Nordisk is cutting list prices up to 50% on Ozempic, Wegovy, and Rybelsus starting January 2027

503A state licensure has been the only compliant compounding path since March 19, 2025